Year-End Report
WILLIAMS AND JENSEN, PLLC for ASTRAZENECA PHARMACEUTICALS LP (FORMERLY ASTRAZENECA PHARMACEUTICALS GROUP)
Income
$100,000
Expenses
—
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare drug benefit; Medicaid drug rebate; drug price negotiation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNY DIJAMES | N/A |
| DAVID E FRANASIAK | N/A |
| JACK STEVEN HART | N/A |
| CHRISTOPHER W HATCHER | N/A |
| SUSAN HIRSCHMANN | N/A |
| KARINA LYNCH | N/A |
| GEORGE OLSEN | N/A |
| JOEL OSWALD | N/A |
Taxation/Internal Revenue Code TAX
Tax issues affecting the drug industry; CFIUS.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNY DIJAMES | N/A |
| DAVID E FRANASIAK | N/A |
| JACK STEVEN HART | N/A |
| CHRISTOPHER W HATCHER | N/A |
| SUSAN HIRSCHMANN | N/A |
| KARINA LYNCH | N/A |
| GEORGE OLSEN | N/A |
| JOEL OSWALD | N/A |
Health Issues HCR
Drug importation and counterfeiting; pediatric trials and studies; drug safety/clinical trials; Follow-On biolgoics; drug advertising; comparative effectiveness; mental health parity; prescription drug user fees; drug payment disclosure legislation; S. 2029.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNY DIJAMES | N/A |
| DAVID E FRANASIAK | N/A |
| JACK STEVEN HART | N/A |
| CHRISTOPHER W HATCHER | N/A |
| SUSAN HIRSCHMANN | N/A |
| KARINA LYNCH | N/A |
| GEORGE OLSEN | N/A |
| JOEL OSWALD | N/A |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.